Skip to main content

Table 1 Patient Demographics and Characteristics

From: Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials

Study ID

Follow-up (week)

Randomized patients

Age (mean)

Male no. (%)

White no. (%)

ASCVD risk factor no. (%)

Baseline LDL-C (mean ± SD) (mg/dl)

Arms

LSM Difference (95% CI) percentage points

Total AEs, no (%)

BA

Placebo

Ray, K. K. 2019 [17] (NCT02666664)

52

2230 (2:1)

66

1628 (73.0)

2139 (95.9)

2176 (97.6)

103.2 ± 29.4

BA+statin vs. placebo +statin

−18.5 (− 20.7, −16.3)

1167 (78.5)

584 (78.7)

Goldberg, A. C. 2019 [18] (NCT02991118)

52

779 (2:1)

64

496 (63.7)

752 (96.5)

736 (94.5)

120.4 ± 37.9

BA+statin vs. placebo +statin

−17.4 (−21, −13.9)

366 (70.1)

182 (70.8)

Lalwani, N. D.2019 [19] (NCT02659397)

4

68 (2:1)

58

35 (51.5)

49 (72.1)

NA

76.4 ± 22.8

BA+Ato vs. placebo +Ato

−22.2(− 36.4,-8.0)

16 (35.6)

5 (21.7)

Ballantyne, C. M.2019 [20] (NCT03337308)

12

301 (2:2:2:1)

64.4

149 (49.5)

243 (80.7)

188 (62.5)

149.7 ± 41

BA+EZE vs. BA/EZE/placebo

−17.8(−25.1,-10.5)/−12.1(−19.1,-5.0)/− 33.7(− 43.9,-23.4)

53 (62.4)

58 (65.9)/47 (54.7)/18 (43.9)

Laufs, U.2019 (NCT02988115) [21]

24

345 (2:1)

65.2

151 (43.8)

307 (89.0)

NA

157.6 ± 39.9

BA vs. placebo

−18.9(−23.0,-14.9)

150 (64.1)

63 (56.8)

Ballantyne, C. M.2018 [22] (NCT03001076)

12

269 (2:1)

64

104 (38.7)

240 (89.2)

269 (100)

127.6

BA+EZE vs. placebo + EZE

−36.5 (− 45.75, − 27.26)

88 (48.6)

39 (44.8)

McGowan, Mary. 2017 [23] (NCT02659397)

4

68 (2:1)

NA

NA

NA

NA

86

BA+statin vs. placebo +statin

−22 (−36.4, − 8)

NA

NA

Thompson, P. D.2016 [24] (NCT01941836)

12

349

60

244 (70.0)

180 (51.6)

131 (37.8)

164.5 ± 25

BA+EZE vs. placebo + EZE

−26.5 (−32.11, − 20.89)

105 (52.8)

31 (62)

Ballantyne, C. M.2016 [25] (NCT02072161)

12

133 (2:1)

57

54 (40.6)

111 (83.4)

NA

135.4 ± 24

BA+statin vs. placebo +statin

−16.7 (−26.7, − 6.7)

43 (48.9)

28 (62)

Thompson, P. D.2015 [26] (NCT01751984)

8

56 (2:1)

62.6

28 (50)

54 (96.4)

NA

179 ± 35.7

BA vs. placebo

−28.7(−35,4,−22.1)

26 (70)

17 (89)

Newton, Roger S 2014 [27]

8

58

NA

NA

NA

NA

NA

BA+statin vs. placebo +statin

-22 (−32.4, −11.6)

NA

NA

Gutierrez, M. J.2014 [28] (NCT01607294)

4

60 (1:1)

55.7

37 (61.7)

57 (95)

NA

126.8 ± 27.8

BA vs. placebo

−39(−46.2,-31.7)

14 (47)

21 (70)

Ballantyne, C. M.2013 [29] (NCT01262638)

12

177 (1:1:1:1)

57

98 (55.4)

152 (85.9)

NA

166.3 ± 24

BA vs. placebo

−21.1(−26,-16.2)

97 (92.9)

33 (75)

  1. Notes: BA Bempedoic acid, EZE Ezetimibe, ASCVD Arteriosclerotic cardiovascular disease, FH Familial hypercholesterolemia, HC Hypercholesterolemia, TC Total cholesterol, LDL-C Low-density lipoprotein cholesterol, Non-HDL-C Non-high- density lipoprotein cholesterol, HDL-C High density lipoprotein cholesterol, ApoB Apolipoprotein, T2DM Type 2 diabetes mellitus